The founders wouldn't say how ownership of BlueRock will be split between Bayer and Versant, the lead investor in gene-editing startup Crispr Therapeutics. Crispr has research operations and a joint venture with Bayer in Cambridge. But the investment round should give the startup a significant opportunity to develop experimental medicines, they said.